Skip to main content
PMC home page
Springer logoLink to Springer
. 2019 Dec 4;127(1):61–70. doi: 10.1007/s00702-019-02109-6

Caregiver burden and health-related quality of life in idiopathic dystonia patients under botulinum toxin treatment: a cross-sectional study

S C Drexel 1,#, M Klietz 1,✉,#, K Kollewe 1, L Paracka 1, A Kutschenko 1, B Kopp 1, F Lange 2, F Wegner 1,#, D Dressler 1,#
PMCID: PMC6942568  PMID: 31802240

Abstract

Dystonia is a chronic movement disorder that is associated with a reduction in health-related quality of life (HR-QoL) and restriction of activities of daily living. Botulinum neurotoxin (BT) improves disease-specific HR-QoL by reducing abnormal movements, postures, and pain. We examined the burden of the corresponding primary caregiver as a potential important factor for disease management and HR-QoL of dystonia patients under treatment with BT. 114 patients with focal, segmental, or generalized dystonia were recruited, together with 93 corresponding caregivers, whose burden was investigated using the Caregiver Burden Inventory. In addition, all participants were assessed for cognitive impairment, depression, anxiety, alexithymia, and HR-QoL. Only a small proportion of caregivers suffered from caregiver burden. Despite BT therapy, patients’ HR-QoL was decreased compared to the age-matched general German population. Psychological symptoms, notably anxiety, and depression correlated significantly with reduced HR-QoL. Our data imply that caregiver burden emerged to be an issue in subgroups of dystonia patients. Furthermore, HR-QoL of dystonia patients is reduced even under optimized BT treatment in a specialized center.

Electronic supplementary material

The online version of this article (10.1007/s00702-019-02109-6) contains supplementary material, which is available to authorized users.

Keywords: Dystonia, Botulinum toxin, Quality of life, Caregiver burden, Depression, Anxiety

Introduction

Dystonia is a chronic movement disorder characterized by abnormal twisted postures, sustained muscle hyperactivity, and pain (Dressler and Benecke 2005). Such dystonic movements are often visible and stigmatizing. Dystonia is classified based on somatic distribution of symptoms (focal, segmental, or generalized), age of disease onset (early or late), and etiology (primary or secondary) (Albanese et al. 2013; Geyer and Bressman 2006). Depending on the population assessed and the methods of ascertainment, focal dystonia affects approximately 8.4–11.9 per 100,000 people (Castelon Konkiewitz et al. 2002). Patients suffering from dystonia report problems with mobility, self-care, or usual daily activities (Gudex et al. 1998), and they also show distinct sensory (Paracka et al. 2017) and cognitive (Jahanshahi 2017; Lange et al. 2016a, b) alterations. Overall, dystonia is mainly seen as a disorder with primary motor symptoms; however, patients can also be affected by consecutive symptoms such as pain and a range of psychological symptoms such as mood disorders.

The treatment of dystonia is symptomatic including botulinum neurotoxin (BT) injections, oral medications, and deep brain stimulation (Dressler et al. 2016). BT is the first line therapy for most types of dystonia and can prevent complications like contractures (Benecke and Dressler 2007; Castelão et al. 2017; Marques et al. 2016). Cervical dystonia without BT treatment is associated with a reduced health-related quality of life (HR-QoL) as measured by the SF-36 (Mordin et al. 2014). The SF-36 scale measures the disease impact on the patient’s activities of daily living, physical, emotional, and social functioning, and is used in many studies assessing HR-QoL in dystonia (Gudex et al. 1998; Müller et al. 2002). It was repeatedly shown that SF-36 scores of untreated dystonia patients in the UK or USA are lower compared to healthy controls (Gudex et al. 1998; Mordin et al. 2014). Other studies showed that under treatment with BT, there is an improvement of disease-specific impairment (Castelão et al. 2017; Marques et al. 2016), HR-QoL (Kongsaengdao et al. 2017), pain, and depression (Weiss et al. 2017). These effects are strongest in the middle of the treatment cycle when BT is exerting its maximal effect. However, the BT effect on HR-QoL as measured by the SF-36 was also described as either mostly statistically insignificant (Gudex et al. 1998) or nonexistent (Kongsaengdao et al. 2017). Dystonia may relate to reduced HR-QoL not only in the affected patients, but also in their caregivers.

Recent studies have shown that caregiver burden is an important factor related to patients’ and caregivers’ HR-QoL in chronic movement disorders such as Parkinson’s disease (Klietz et al. 2019; Schmotz et al. 2017). The concept of caregiver burden is a multidimensional construct that summarizes the adverse effects of giving care for a person (e.g., financial, emotional, social, psychological, and physical) on the functioning of the caregiver (Zarit et al. 1986). Currently, little is known about burden of caregivers of dystonia patients in Germany. Therefore, we examined the HR-QoL of all subtypes of patients with idiopathic dystonia and their corresponding primary caregivers—as well as the related burden—as potentially important modulators of the management of dystonia in a cross-sectional design.

Methods

Participants

We obtained approval from the local Ethics Committee of Hannover Medical School (No. 7927_BO_K_2018), and all patients as well as their caregivers gave written informed consent. We enrolled 114 patients with dystonia and their caregivers at Hannover Medical School. 21 caregivers did not complete all questionnaires which renders a final sample of N = 114 patients and N = 93 caregivers. Inclusion criteria were defined as adult age of patient and caregiver, neurologically confirmed diagnosis of idiopathic dystonia and a non-professional caregiving situation at home. Patients with professional care or a neurological diagnosis of dementia were excluded from this analysis. The overwhelming majority of patients (98.3%) was under treatment with BT in 3-month intervals.

Measures

All patients were seen by one trained examiner at the day that they received BT injections and dystonic symptoms were evaluated by Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS-I motor score, BFMDRS-II disability score) (Burke et al. 1985). Furthermore, the German version of Montreal Cognitive Assessment (MoCA) was used to evaluate cognitive functioning (Nasreddine et al. 2005). All patients suffering from a cervical dystonia were also assessed with the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) (Consky et al. 1990) and the craniocervical dystonia questionnaire (CDQ-24) for disease-specific HR-QoL (Mueller et al. 2016). All participants (patients and their caregivers) were asked to complete the WHO Short Form 36 (SF-36) Health Survey for assessment of their HR-QoL (Ware and Donald-Sherbourne 1992), the Beck Depression Inventory (BDI) (Beck et al. 1961), the Toronto-Alexithymia Scale (TAS-26) (Bagby et al. 1994), and the STAI (STAI-S state anxiety and STAI-T trait anxiety) (Spielberger et al. 1983). In addition, primary caregivers were asked to complete the Caregiver Burden Inventory (CBI) (Zarit et al. 1980). The CBI comprises 22 items and a total score ranging from 0 (lowest burden) to 88 (highest burden), less than 20 points, suggest the absence of significant burden, 21–40 points are considered indicating mild, 41–60 points indicating moderate, and 61–88 points indicating severe burden. Patients’ and caregivers’ age, educational level, and relationship to caregiver were also recorded, together with patients’ years since diagnosis and the caregivers’ daily amount of time.

Analyses

We performed a univariate regression model for the association of average SF-36 scores with sum scores of investigated predictors (Supplement Table 1). All items that were significant with p < 0.05 were included in a multivariate regression model to test against co-correlations and confounding. A back-to-back selection to the significance level of 5% was carried out. Furthermore, we performed a univariate regression model for the association of CBI scores with sum scores of investigated predictors (Supplement Table 2). All items that were significant with p < 0.05 were included in a multivariate regression model to test against co-correlations and confounding. A back-to-back selection to the significance level of 5% was carried out. To explore significant differences between the group of burdened and unaffected caregivers, we used an unpaired t test with independent variables for the evaluated predictors of caregiver burden. To correct for multiple comparisons, the significance level has been adjusted to 0.05/n. Descriptive statistics and Pearson-regression analyses were carried out using SPSS 25.0 (IBM, Armonk, NY).

Results

Caregiver characteristics

93 caregivers completed all questionnaires, 36.6% of them were female. Mean age of caregivers was 61.6 years (± 13.5, min 27, max 86). Most caregivers had a middle (37.6%) or low (34.4%) level of education, and 80.7% of them were spouses of the related dystonia patient.

Caregivers spent an average of 2.2 h per day (± 5.3, min 0, max 24) with caregiving activities, e.g., support in mobility and self-care. On average the CBI score was 8.6 (± 9.6, min 0, max 48) suggesting no caregiver burden. Caregivers had a mean BDI score of 6.0 (± 5.9, min 0, max 26), indicating no depressive symptoms. The TAS-26 was on average 2.4 (± 0.5) not suggestive for alexithymia. In terms of anxiety, caregivers also showed an average degree of state and trait anxiety indicated by a mean STAI-S score of 38 (± 10.7, min 20, max 66), and an STAI-T score of 35.5 (± 9.9, min 21, max 63), respectively. All caregiver characteristics are summarized in Table 1. The caregivers’ mean SF-36 score was 72.5 points (± 17.9, min 24.2, max 95.3); for comparison with patients’ SF-36 data, see Fig. 1.

Table 1.

Demographic and clinical data of caregivers

Item Distribution N = 93
Sex N females 34 (36.6%)
N males 59 (63.4%)
Age Mean ± SD 61.6 ± 13.5
Range 27–86
N missing data 0
Educational level High 22 (23.7%)
Middle 35 (37.6%)
Low 32 (34.4%)
Missing data 4 (4.3%)
Relationship with patient Spouses and life partner 75 (80.7%)
Daughter/son 9 (9.7%)
Sister/brother 2 (2.2%)
Other related persons 5 (5.4%)
Missing data 2 (2.2%)
Caregiving, h/day Mean ± SD 2.2 ± 5.3
Range 0–24
Missing data 2 (2.2%)
CBI Mean ± SD 8.6 ± 9.6
Range 0–48
Missing data 0
BDI Mean ± SD 6 ± 5.9
Range 0–26
Missing data 11 (11.8%)
TAS-26 Mean ± SD 2.4 ± 0.5
Range 1.3–3.7
Missing data 4 (4.3%)
STAI-S Mean ± SD 38 ± 10.7
Range 20–66
Missing data 3 (3.2%)
STAI-T Mean ± SD 35.5 ± 9.9
Range 21–63
Missing data 2 (2.2%)
SF-36 Mean ± SD 72.5 ± 17.9
Range 24.2–95.3
Missing data 0
Open in a new tab

CBI Caregiver Burden Inventory, BDI Beck Depression Inventory, TAS-26 Toronto-Alexithymia Scale, STAI-S state anxiety, STAI-T trait anxiety State–Trait–Anxiety Inventory, SD standard deviation, SF-36 WHO Short Form 36 Health Survey

Fig. 1.

Fig. 1

Open in a new tab

Health-related quality of life (HR-QoL) measured by Short Form 36 in patients with dystonia and their caregivers compared to the age-matched general German population. Bar graph comparing the HR-QoL of our study patients (light grey) and caregivers (black) with the general German population (data from 2003) (white). All SF-36 subscales are significantly reduced in the dystonia patients compared to the German age-matched population. Caregivers HR-QoL did not show significant differences in comparison to the German age-matched population. *p < 0.001

Overall, our results suggest only a low amount of caregiver burden. Therefore, we wanted to compare the caregivers who reported relevant burden (N = 9, CBI score ≥ 20) and the caregivers without (N = 84, CBI score < 20) in a subgroup analysis to identify additional potential risk factors for higher caregiver burden. In comparison with the unburdened caregivers, the group of burdened caregivers showed significantly higher BDI scores and lower HR-QoL, similar to their related patients (Table 2).

Table 2.

Comparison of non-burdened caregivers’ characteristics with burdened caregivers’ characteristics

Item Non-burdened (CBI < 20) Burdened (CBI ≥ 20) Unpaired t test
N = 84 N = 9
Caregivers’ properties Age 61.1 ± 13.5 66.7 ± 12.4 0.244
CG h/d 1.9 ± 5.2 4.6 ± 6.0 0.162
SF-36 74.2 ± 17.1 56.3 ± 16.0 0.004**
BDI 5.3 ± 5.6 12.2 ± 5.1 0.001**
Dystonia patients’ properties Age 63.9 ± 10.6 65 ± 16.0 0.853
BFMDRS-I 11.3 ± 11.2 21.8 ± 22.5 0.234
BFMDRS-II 2.2 ± 2.9 7.0 ± 9.8 0.205
SF-36 57.7 ± 20.7 37.7 ± 10.6 0.001**
BDI 10.2 ± 8.4 17.4 ± 8.9 0.075
MoCA 25.8 ± 2.7 21.9 ± 5.1 0.124
Open in a new tab

This table displays the difference between non-burdened caregivers (CBI < 20) and burdened caregivers (CBI ≥ 20). Non-burdened caregivers’ SF scores are significantly higher than burdened caregivers’ scores, also the SF-36 scores of the corresponding patients are significantly higher, BDI scores of the non-burdened caregivers are significantly lower than BDI scores of the burdened caregivers

Table 3 Unpaired t test (*p < 0.05, **p < 0.005) between caregivers with and without burden. Data of corresponding dystonia patients are shown above

CBI Caregiver Burden Inventory, CG h/d caregiving hours/day, SF-36 WHO Short Form 36 Health Survey, BDI Beck Depression Inventory, BFMDRS-I motor score, BFMDRS-II disability score Burke–Fahn–Marsden Dystonia Rating Scale, MoCA Montreal Cognitive Assessment

We performed a univariate regression model for the association of the CBI score with sum scores of investigated predictors. The univariate regression with adjusted significance level of p < 0.004 showed significant correlations for the CBI score with the caregiving hours per day (b = 0.329, r = 0.409, p = 0.001), the patients’ average SF-36 scores (b = 0.392, r = − 0.379, p < 0.001), and the patients’ STAI-T (b = 0.333, r = 0.323, p = 0.001). Furthermore, the univariate regression showed significant correlations for the CBI score with the caregivers’ average SF-36 scores (b = 0.217, r = − 0.214, p = 0.038), the caregivers’ STAI-S (b = 0.225, r = 0.220, p = 0.033), the patients’ STAI-S (b = 0.295, r = 0.288, p = 0.005), the caregivers’ STAI-T (b = 0.240, r = 0.243, p = 0.022), the BFMDRS-I (b = 0.216, r = 0.215, p = 0.049), the BFMDRS-II (b = 0.280, r = 0.284, p = 0.010), and the patients’ TAS-26 score (b = 0.218, r = 0.211, p = 0.040). A back-to-back selection at a significance level of 5% was carried out for a multivariate regression model. After 8 runs, the caregiving hours per day (b = 0.313, r = 0.395, p = 0.03) and the patients’ STAI-T (b = 0.378, r = 0.366, p < 0.001) remained significantly correlated with the CBI.

Patient characteristics

We screened 175 dystonia patients during data collection. 114 patients completed all questionnaires, 72.8% of them were females. On average, the included 114 patients were 64.0 years old (± 11.1 standard deviation, min 30, max 85). Mean time under diagnosis was 14 years (± 9.4, min 0, max 48). Patients’ average BFMDRS-I score was 11.7 (± 13) and the BFMDRS-II score was 2.4 (± 4). Patients suffering from a cervical dystonia had an average TWSTRS score of 27.4 (± 13.9).

The majority of the participants had a middle (43.0%) or low (42.1%) level of education. The cognitive function of the patients turned out to be normal with a mean MoCA score of 25.5 (± 3.1, min 12, max 30). A severe cognitive impairment, corresponding to an MoCA score below 21 points, was only found in 7.9% of all patients. Our patients had a mean BDI score of 10.7 (± 8.7, min 0, max 45) suggesting no depressive syndrome. However, 4.4% of our patients suffered from marked symptoms of depression, 7.9% from moderate, and 14.0% from mild depressive symptoms. Similarly, there was no sign of alexithymia in our patient sample. The TAS-26 was on average 2.5 (± 0.5, min 1.22, max 3.81) with no major difference to the standard cutoff for alexithymia of 2.4 (± 0.5) and below. In terms of anxiety, our patients showed an average degree of state and trait anxiety indicated by a mean STAI-S score of 40.5 (± 12.1, min 22, max 69), and an STAI-T score of 40.8 (± 11, min 21, max 69). All patient characteristics are summarized in Table 3.

Table 3.

Demographic and clinical data of dystonia patients

Item Distribution N = 114
Sex N females 83 (72.8%)
N males 31 (27.2%)
Age Mean ± SD 64 ± 11.1
Range 30–85
N missing data 2 (1.8%)
Educational level High 14 (12.3%)
Middle 49 (43%)
Low 48 (42.1%)
Missing data 3 (2.6%)
Years since diagnosis Mean ± SD 14 ± 9.4
Range 0–48
Missing data 8 (7%)
BFMDRS-I Mean ± SD 11.7 ± 13
Range 0.5–72
Missing data 11 (9.7%)
BFMDRS-II Mean ± SD 2.4 ± 4
Range 0–29
Missing data 11 (9.7%)
TWSTRS (only cervical dystonia patients) Mean ± SD 27.4 ± 13.9
Range 0–63.5
Missing data 10 (15.2%)
MoCA total score Mean ± SD 25.5 ± 3.1
Range 12–30
Missing data 12 (10.5%)
BDI Mean ± SD 10.7 ± 8.7
Range 0–45
Missing data 1 (0.9%)
TAS-26 Mean ± SD 2.5 ± 0.5
Range 1.2 3.8
Missing data 3 (2.6%)
STAI-S Mean ± SD 40.5 ± 12.1
Range 22–69
Missing data 2 (1.8%)
STAI-T Mean ± SD 40.8 ± 11
Range 21–69
Missing data 2 (1.8%)
SF-36 Mean ± SD 56.3 ± 20.8
Range 10.4–94.9
Missing data 0 (0%)
Open in a new tab

BFMDRS-I motor score, BFMDRS-II disability score Burke–Fahn–Marsden Dystonia Rating Scale, TWSTRS Toronto Western Spasmodic Torticollis Rating Scale, MoCA Montreal Cognitive Assessment, BDI Beck Depression Inventory, TAS-26 Toronto-Alexithymia Scale, State–Trait–Anxiety Inventory, standard deviation

We investigated 89 patients with focal, 16 with segmental, and 9 with generalized dystonia. Table 4 displays all dystonia subgroups included in our study (multiple subtypes were possible, e.g., focal and blepharospasm). Across all subgroups, our patients had an average SF-36 score of 56.3 (± 28.3, min 0, max 100). The HR-QoL is decreased compared to a general age-matched German population. Figure 1 displays the patients’ SF-36 sub scores, the age-matched German population data from 2003, and, additionally, caregivers’ HR-QoL (Kurth and Ellert 2002). It is notable that, on average, patients with focal dystonia had higher SF-36 scores than patients with segmental or generalized dystonia (Table 4).

Table 4.

Clinical data of dystonia subtypes in our cohort (N = 114 patients, multiple subtypes possible, e.g., focal and blepharospasm)

Dystonia N Item Mean ± SD Range
Focal 89 BFMDRS-I 8.2 ± 8.3 0.5–58
BFMDRS-II 1.4 ± 2.1 0–11
SF-36 58.8 ± 20.8 19.6–94.9
Segmental 16 BFMDRS-I 12.2 ± 5 4–20
BFMDRS-II 2.4 ± 1.9 0–6
SF-36 50.6 ± 18.5 22.5–81.7
Generalized 9 BFMDRS-I 41.6 ± 17.5 16.5–72
BFMDRS-II 10.8 ± 7.4 3–29
SF-36 43 ± 17.8 10.4–69.9
Blepharospasm 16 BFMDRS-I 5.8 ± 4.3 1–20
BFMDRS-II 0.6 ± 1.4 0–6
SF-36 56.4 ± 21.1 29.6–89.9
Cervical dystonia 66 BFMDRS-I 8.9 ± 9.3 0.5–58
BFMDRS-II 1.5 ± 2.2 0–11
SF-36 58.5 ± 20.2 19.6–94.9
TWSTRS 26.2 ± 12.7 3–57
CDQ-24 33.4 ± 19.1 0–86.2
Open in a new tab

BFMDRS-I motor score, BFMDRS-II disability score Burke–Fahn–Marsden Dystonia Rating Scale, MoCA Montreal Cognitive Assessment, BDI Beck Depression Inventory, TWSTRS Toronto Western Spasmodic Torticollis Rating Scale, CDQ-24 Craniocervical Dystonia Questionnaire, SD standard deviation

We performed a univariate regression model for the association of average SF-36 scores with sum scores of investigated predictors. Our univariate regression analysis with adjusted significance level of p < 0.006 showed significant negative correlations for the patients’ BDI (b = 0.352, r = − 0.531, p < 0.001), STAI-S (b = 0.407, r = − 0.414, p < 0.001), and STAI-T score (b = 0.358, r = − 0.359, p < 0.001). Furthermore, the univariate regression showed significant negative correlations for the patients’ average SF-36 score, the disability scale BFMDRS-II (b = 0.198, r = − 0.211, p = 0.047), and TAS-26 score (b = 0.211, r = − 0.210, p = 0.028). To test against co-correlations and confounding of patients’ variables, the BFMDRS-II, BDI, TAS-26, STAI-S, and STAI-T, which were significant in the univariate model, were examined in a multivariate model. A back-to-back selection at a significance level of 5% was carried out. After six runs, STAI-S (b = 0.296, r = − 0.306, p = 0.006) and BDI scores (b = 0.220, r = − 0.333, p = 0.041) were significantly correlated with patients’ HR-QoL.

Discussion

In the present study, we examined caregiver burden in a group of dystonia patients and their caregivers, together with the HR-QoL of patients and their caregivers. Patients’ trait anxiety (as measured by the STAI) as well as the number of caregiving hours per day emerged as predictors of unique variance in the burden experienced by caregivers of patients with dystonia. In addition, we found that, even under treatment with BT, dystonia patients have a decreased HR-QoL in all SF-36 sub scores (Fig. 1) compared to their caregivers and the general German population (Kurth and Ellert 2002). Our statistical analysis shows a significant negative correlation between lower SF-36 and higher STAI-S and BDI scores of the patients. Hence, depression and state anxiety seem to account for HR-QoL in dystonia, similar data could already be shown in Parkinson’s disease (Aarsland et al. 1999, 2007; Carod-Artal et al. 2013; Martínez-Martín et al. 2007).

Caregiver burden

In Parkinson’s disease, caring for a family member has been recognized to negatively impact the caregivers’ life in physical, emotional, and psychosocial aspects, associated with an increased risk of psychiatric morbidity and persistent distress (Greenwell et al. 2014). Non-motor symptoms of the patient consistently make a greater contribution to caregiver burden than motor symptoms. In particular, patients’ anxiety (Carod-Artal et al. 2013; Leiknes et al. 2010), depression (Aarsland et al. 1999; Martínez-Martín et al. 2007), and cognitive impairment (Coelho et al. 2015) are an important predictor of caregiver burden. The identification and timely treatment of caregiver burden also have a substantial economic benefit for society in addition to the health-related benefits to the patient (Martinez-Martin et al. 2019a).

So far, to our knowledge, no data on caregiver burden have been available for dystonia. In our large sample, we found only a low amount of caregiver burden. Factors explaining this could be the preserved patients’ autonomy due to the treatment with BT and the low amount of daily caregiving. The latter explanation is supported by the results of our multivariate regression analysis, which demonstrated that the number of caregiving hours is positively linked to reported caregiver burden. In addition, this analysis identified depression and cognitive impairment as unique predictors of caregiver burden, suggesting that, for the few caregivers with relevant burden (CBI > 20), the related patients suffered from even less HR-QoL, more depression and slightly more cognitive impairment. The limited variance in detected caregiver burden might underestimated the role of possible variance-explaining predictors. There was no particular type of dystonia associated with higher caregiver burden, but the corresponding patients had more severe dystonic symptoms as assessed by the BFMDRS-I and BFMDRS-II. Further research should focus on major groups of patients with generalized dystonia or more severe dystonic symptoms.

HR-QoL in dystonia patients

In general, dystonia is associated with a reduction of HR-QoL (Mordin et al. 2014). Patients suffering from dystonia reported more problems with daily activities, e.g., mobility and self-care (Gudex et al. 1998). In addition, only a minority of the patients reported complete satisfaction with their treatment at the end of a botulinum toxin (BT) therapy cycle as recently shown in large study groups (Colosimo et al. 2019; Misra et al. 2018). This is in line with our observation on decreased HR-QoL, as we detected a persistent reduction in patients’ SF-36 scores, even under chronic treatment with BT, compared to general German population data. While we used age-matched control data, our study group had a slightly higher female proportion of 72.8%. Since women tend to achieve lower SF-36 scores (Ellert and Kurth 2013), the difference between our data and the control cohort may actually be smaller. However, if the data for an all-female control are taken as a basis, the effect remains clearly significant (data not shown).

Several previous studies also found a high prevalence of depression and anxiety in patients with dystonia (Gündel et al. 2003; Moraru et al. 2002; Wenzel et al. 1998), which emphasizes these symptoms as an important factor in the disease process. Our statistical analysis also indicated that the reduced HR-QoL is mainly associated with symptoms beyond motor impairment, such as depression and anxiety. This is in line with Ben-Shlomo et al. (2002), Conte et al. (2015) and Page et al. (Page et al. 2007), who have already suggested that these neuropsychological symptoms are the main predictors for HR-QoL in dystonia. Similar results were found for patients with Parkinson’s disease (Aarsland et al. 2009; Klietz et al. 2018).

Remarkably, the severity of dystonia, as measured by the BFMDRS-I or TWSTRS, showed no statistically significant correlation with HR-QoL, although all patients were examined in the wearing-off of the BT treatment with probably the greatest extent of motor symptoms. In addition, patients’ treatment satisfaction seemed to be stable, even if clinical features were improved as measured by TWSTRS and Tsui scale (Colosimo et al. 2019). This matches prior results, suggesting that severity of dystonia is a weaker predictor for HR-QoL in dystonia than depression and anxiety (Ben-Shlomo et al. 2002; Page et al. 2007). Similar results have been obtained by Smit et al. (2016). Czekóová et al. (2017) found a reduced emotional awareness or alexithymia in patients with cervical dystonia, suggesting that this could be another predictor for reduced HR-QoL. However, we did not find a relevant proportion of alexithymia as measured by the TAS-26 in our sample. When treated with BT, motor symptoms may be negligible as main predictor of HR-QoL in most dystonia patients. Since these non-motor symptoms are not fully addressed by BT, these symptoms seemed to be predominant in our patients undergoing chronic BT treatment and were associated with poorer HR-QoL. It, therefore, seems useful for patients suffering from dystonia, in addition to an assessment of motor symptoms, to carry out an assessment of the coexisting non-motor symptoms (depression, anxiety, cognitive impairment). A quick and clinically useful self-assessment, similar to the Movement Disorder Society Non-motor Scale (MDS-NMS) for Parkinson’s disease (Martinez-Martin et al. 2019b), was recently published for dystonia patients (Klingelhoefer et al. 2019). Our results provide further evidence for the profound impact of dystonia on patients’ HR-QoL. The mismatch between objective BT-induced improvement of dystonia and HR-QoL, which still seems to be affected, as determined by the SF-36, illustrates the need for a specific therapy of these non-motor symptoms. In the long run, it might prove beneficial to support patients by pharmacological and/or psychological treatment, so that they will be able to cope with their neuropsychological symptoms and restriction of activities of daily living.

Further large-scale studies with de novo patients are needed to examine neuropsychological symptoms, pain, and sleep disorders, and their impact on HR-QoL in dystonia.

Limitation

Despite the fact that we examined a large cohort of patients with dystonia and their caregivers, a limiting factor remains the different group sizes of the dystonia subtypes. In addition, our study cohort contains hardly any de novo patients, so there is no direct comparison to the reduced HR-QoL of untreated dystonia patients and their caregivers.

Even though we could show substantial evidence of a decreased HR-QoL in our patients, only low caregiver burden could be detected. The CBI as a measuring instrument for caregiver burden is not specific to dystonia, but nevertheless, the gold standard for evaluating caregiver burden internationally.

Another limitation arises from the small number of caregivers for generalized dystonia patients who reported a higher caregiver burden. In future studies, a multicentric approach should enable to investigate more patients with generalized dystonia and their caregivers.

Conclusion

In our patients with dystonia, the related caregiver burden appeared to be low and only mildly related to HR-QoL of the caregiver. For a small subgroup of patients with marked dystonic symptoms and pronounced HR-QoL deficits, burden of the corresponding caregiver seemed to be an issue. Therefore, we propose to perform a corresponding assessment when caregiver burden is suspected. To implement an individual intervention, an improved caregiver education about the patients’ disease, a reduction of the daily caregiving hours, and a better social support can be established. To our knowledge, this is the first caregiver burden study in a larger group of patients with dystonia. Further studies are needed to describe caregiver burden in the subgroup of patients suffering from severe dystonia.

Notwithstanding the fact that all dystonia patients received optimized treatment with BT, their HR-QoL was still reduced. Despite a relief of their symptoms, they still suffered from dystonic symptoms and a chronic disease. This might partly explain the reduction in HR-QoL and more severe depressive symptoms in the patient cohort. Overall, our data indicate that effective treatment of dystonia patients has to include screening and management of neuropsychiatric symptoms which should be addressed in future multicentric studies.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 13 kb) (13.8KB, docx)

Acknowledgements

We thank all the patients and caregivers for participating in our study. The statistical counselling of L. Aguirre Davila and S. Häckl of the Institute of Biometrics of Hannover Medical School is gratefully acknowledged. We thank M.H. Elaman for reviewing the language quality of the manuscript.

Author contributions

MK, DD, and FW: designed the study and developed the methodological conception; MK and SD: implemented the assessment tools for data collection; MK, KK, LP, AK, and SD: were responsible for the patient recruitment; SD: performed the data collection and digitalization; MK and SD: analyzed the data; SD and MK: wrote the first draft of this manuscript; FL, BK, FW, and DD: made substantial contributions to the writing and language editing of the final draft and enhanced the quality of the manuscript by revising it critically for important intellectual content. All authors have given approval to the final version of the manuscript.

Funding

This study was supported by a grant of the German “Arbeitskreis Botulinum Toxin” to MK.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to report.

Footnotes

Disclaimer

The sponsor had no influence on the carrying out of the study or the writing of the manuscript.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

S.C. Drexel and M. Klietz contributed equally.

F. Wegner and D. Dressler contributed equally.

References

  1. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriat Psychiatry. 1999;14:866–874. doi: 10.1002/(SICI)1099-1166(199910)14:10&#x0003c;866::AID-GPS38&#x0003e;3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  2. Aarsland D, Brønnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. JNNP. 2007;78:36–42. doi: 10.1136/jnnp.2005.083113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24:2175–2186. doi: 10.1002/mds.22589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VSC, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28:863–873. doi: 10.1002/mds.25475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bagby RM, Parker JDA, Taylor GJ. The twenty-item Toronto Alexithymia scale—I. Item selection and cross-validation of the factor structure. J Psychosom Res. 1994;38:23–32. doi: 10.1016/0022-3999(94)90005-1. [DOI] [PubMed] [Google Scholar]
  6. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
  7. Benecke R, Dressler D. Botulinum toxin treatment of axial and cervical dystonia. Disabil Rehabil. 2007;29:1769–1777. doi: 10.1080/01421590701568262. [DOI] [PubMed] [Google Scholar]
  8. Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry. 2002;72:608–614. doi: 10.1136/jnnp.72.5.608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology. 1985;35:73–77. doi: 10.1212/wnl.35.1.73. [DOI] [PubMed] [Google Scholar]
  10. Carod-Artal FJ, Mesquita HM, Ziomkowski S, Martinez-Martin P. Burden and health-related quality of life among caregivers of Brazilian Parkinson’s disease patients. Parkinsonism Relat Disord. 2013;19:943–948. doi: 10.1016/j.parkreldis.2013.06.005. [DOI] [PubMed] [Google Scholar]
  11. Castelão M, Marques RE, Duarte GS, Rodrigues FB, Ferreira J, Sampaio C, Moore AP, Costa J. Botulinum toxin type A: therapy for cervical dystonia. Cochrane Database Syst Rev. 2017 doi: 10.1002/14651858.CD003633.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Castelon Konkiewitz E, Trender-Gerhard I, Kamm C, Warner T, Ben-Shlomo Y, Gasser T, Conrad B, Ceballos-Baumann AO. Service-based survey of dystonia in Munich. Neuroepidemiology. 2002;21:202–206. doi: 10.1159/000059525. [DOI] [PubMed] [Google Scholar]
  13. Coelho M, Marti MJ, Sampaio C, Ferreira JJ, Valldeoriola F, Rosa MM, Tolosa E. Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson’s disease: the Barcelona–Lisbon cohort. Eur J Neurol. 2015;22:305–312. doi: 10.1111/ene.12567. [DOI] [PubMed] [Google Scholar]
  14. Colosimo C, Charles D, Misra VP, Maisonobe P, Om S. How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. J Neurol. 2019 doi: 10.1007/s00415-019-09527-2. [DOI] [PubMed] [Google Scholar]
  15. Consky ES, Basinki A, Belle L, Ranawaya R, Lang AE. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of the validity and inter-rater reliability. Neurology. 1990;40:445–450. [Google Scholar]
  16. Conte A, Berardelli I, Ferrazzano G, Pasquini M, Berardelli A, Fabbrini G. Non-motor symptoms in patients with adult-onset focal dystonia: sensory and psychiatric disturbances. Parkinsonism Relat Disord. 2015;22:111–114. doi: 10.1016/j.parkreldis.2015.09.001. [DOI] [PubMed] [Google Scholar]
  17. Czekóová K, Zemánková P, Shaw D, Bareš M. Social cognition and idiopathic isolated cervical dystonia. J Neural Transm. 2017;124:1097–1104. doi: 10.1007/s00702-017-1725-8. [DOI] [PubMed] [Google Scholar]
  18. Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurol. 2005;252:1299–1306. doi: 10.1007/s00415-005-0006-x. [DOI] [PubMed] [Google Scholar]
  19. Dressler D, Altenmueller E, Bhidayasiri R, Bohlega S, Chana P, Chung T, Frucht S, Garcia-Ruiz P, Kaelin A, Kaji R, Kanovsky P, Laskawi R, Micheli F, Orlova O, Relja M, Rosales R, Slawek J, Timerbaeva S, Warner T, Saberi F. Strategies for treatment of dystonia. J Neural Transm. 2016;123:251–258. doi: 10.1007/s00702-015-1453-x. [DOI] [PubMed] [Google Scholar]
  20. Ellert U, Kurth BM. Gesundheitsbezogene Lebensqualität bei Erwachsenen in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5):643–649. doi: 10.1007/s00103-013-1700-y. [DOI] [PubMed] [Google Scholar]
  21. Geyer HL, Bressman SB. The diagnosis of dystonia. Lancet Neurol. 2006;5:780–790. doi: 10.1016/S1474-4422(06)70547-6. [DOI] [PubMed] [Google Scholar]
  22. Greenwell K, Gray WK, van Wersch A, van Schaik P, Walker R. Predictors of the psychosocial impact of being a carer of people living with Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2014;21:1–11. doi: 10.1016/j.parkreldis.2014.10.013. [DOI] [PubMed] [Google Scholar]
  23. Gudex CM, Hawthorne MR, Butler AG, Duffey P. Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord. 1998;13:941–946. doi: 10.1002/mds.870130613. [DOI] [PubMed] [Google Scholar]
  24. Gündel H, Wolf A, Xidara V, Busch R, Ladwig K, Jacobi F, Von Rad M, Ceballos-Baumann A. High psychiatric comorbidity in spasmodic torticollis: a controlled study. J Nerv Ment Dis. 2003;191:465–473. doi: 10.1097/01.NMD.0000081667.02656.21. [DOI] [PubMed] [Google Scholar]
  25. Jahanshahi M. Neuropsychological and neuropsychiatric features of Idiopathic and DYT1 dystonia and the impact of medical and surgical treatment. Arch Clin Neuropsychol. 2017;32:888–905. doi: 10.1093/arclin/acx095. [DOI] [PubMed] [Google Scholar]
  26. Klietz M, Tulke A, Müschen LH, Paracka L, Schrader C, Dressler D, Wegner F. Impaired quality of life and need for palliative care in a german cohort of advanced parkinson’s disease patients. Front Neurol. 2018;9:120. doi: 10.3389/fneur.2018.00120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Klietz M, Rippena L, Lange F, Tulke A, Paracka L, Dressler D, Wegner F. Validating the Parkinson’s disease caregiver burden questionnaire (PDCB) in German caregivers of advanced Parkinson’s disease patients. Int Psychogeriatr. 2019 doi: 10.1017/s1041610219000206. [DOI] [PubMed] [Google Scholar]
  28. Klingelhoefer L, Chaudhuri KR, Kamm C, Martinez-Martin P, Bhatia K, Sauerbier A, Kaiser M, Rodriguez-Blazquez C, Balint B, Untucht R, Hall LJ, Mildenstein L, Wienecke M, Martino D, Gregor O, Storch A, Reichmann H. Validation of a self-completed dystonia non-motor symptoms questionnaire. Ann Clin Transl Neurol. 2019 doi: 10.1002/acn3.50900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kongsaengdao S, Maneeton B, Maneeton N. Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study. Neuropsychiatr Dis Treat. 2017;13:127–132. doi: 10.2147/NDT.S116325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kurth BM, Ellert U. The SF-36 questionnaire and its usefulness in population studies: results of the German Health Interview and Examination Survey 1998. Soz Praventivmed. 2002;47:266–277. doi: 10.1007/s00038-002-8217-8. [DOI] [PubMed] [Google Scholar]
  31. Lange F, Seer C, Dengler R, Dressler D, Kopp B. Cognitive flexibility in primary dystonia. JINS. 2016;22:662–670. doi: 10.1017/S135561771600045X. [DOI] [PubMed] [Google Scholar]
  32. Lange F, Seer C, Salchow C, Dengler R, Dressler D, Kopp B. Meta-analytical and electrophysiological evidence for executive dysfunction in primary dystonia. Cortex. 2016;82:133–146. doi: 10.1016/j.cortex.2016.05.018. [DOI] [PubMed] [Google Scholar]
  33. Leiknes I, Tysnes OB, Aarsland D, Larsen JP. Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson’s disease: the Norwegian ParkWest study. Acta Neurol Scand. 2010;122:418–424. doi: 10.1111/j.1600-0404.2010.01332.x. [DOI] [PubMed] [Google Scholar]
  34. Marques RE, Duarte GS, Rodrigues FB, Castelão M, Ferreira J, Sampaio C, Moore AP, Costa J. Botulinum toxin type B for cervical dystonia: systematic review. Cochrane Database Syst Rev. 2016 doi: 10.1002/14651858.CD004315.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K. The long-term direct and indirect economic burden among Parkinson’s disease caregivers in the United States. Mov Disord. 2019;34:236–245. doi: 10.1002/mds.27579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Martinez-Martin P, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Chaudhuri KR. Pilot study of the international Parkinson and movement disorder society-sponsored non-motor rating scale (MDS-NMS) Mov Disord. 2019;6:227–234. doi: 10.1002/mdc3.12728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Martínez-Martín P, Forjaz MJ, Frades-Payo B, Rusiñol AB, Fernández-García JM, Benito-León J, Arillo VC, Barberá MA, Sordo MP, Catalán MJ. Caregiver burden in Parkinson’s disease. Mov Disord. 2007;22:924–931. doi: 10.1002/mds.21355. [DOI] [PubMed] [Google Scholar]
  38. Misra V, Colosimo C, Charles D, Chung T, Maisonobe P, Om S. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. J Neurol. 2018;265:402–409. doi: 10.1007/s00415-017-8698-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Moraru E, Schnider P, Wimmer A, Wenzel T, Birner P, Griengl H, Auff E. Relation between depression and anxiety in dystonic patients: implications for clinical management. Depress Anxiety. 2002;16:100–103. doi: 10.1002/da.10039. [DOI] [PubMed] [Google Scholar]
  40. Mordin M, Masaquel C, Abbott C, Copley-Merriman C. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open. 2014 doi: 10.1136/bmjopen-2014-005150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Mueller J, Wissel J, Kemmler G, Voller B, Bodner T, Schneider A, Wenning GK, Poewe W. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. Acta Neurol Belg. 2016;116:589–592. doi: 10.1007/s13760-016-0634-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Müller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol. 2002;249:842–846. doi: 10.1007/s00415-002-0733-1. [DOI] [PubMed] [Google Scholar]
  43. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699. doi: 10.1111/j.1532-5415.2005.53221.x. [DOI] [PubMed] [Google Scholar]
  44. Page D, Butler A, Jahanshahi M. Quality of life in focal, segmental, and generalized dystonia. Mov Disord. 2007;22:341–347. doi: 10.1002/mds.21234. [DOI] [PubMed] [Google Scholar]
  45. Paracka L, Wegner F, Blahak C, Abdallat M, Saryyeva A, Dressler D, Karst M, Krauss JK. Sensory alterations in patients with isolated idiopathic dystonia: an exploratory quantitative sensory testing analysis. Front Neurol. 2017;8:553. doi: 10.3389/fneur.2017.00553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Schmotz C, Richinger C, Lorenzl S. High burden and depression among late-stage idiopathic parkinson disease and progressive supranuclear palsy caregivers. J Geriatr Psychiatry Neurol. 2017;30(267):272. doi: 10.1177/0891988717720300. [DOI] [PubMed] [Google Scholar]
  47. Smit M, Kuiper A, Han V, Jiawan VCR, Douma G, van Harten B, Oen JMTH, Pouwels ME, Dieks HJG, Bartels AL, Tijssen MA. Psychiatric co-morbidity is highly prevalent in idiopathic cervical dystonia and significantly influences health-related quality of life: results of a controlled study. Parkinsonism Relat Disord. 2016;30:7–12. doi: 10.1016/j.parkreldis.2016.06.004. [DOI] [PubMed] [Google Scholar]
  48. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the state-trait anxiety inventory. Palo Alto: Consulting Psychologists Press; 1983. [Google Scholar]
  49. Ware JE, Donald-Sherbourne C. The MOS 36 item short form health survey (SF 36) I. conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002. [DOI] [PubMed] [Google Scholar]
  50. Weiss D, Hieber L, Sturm J, Börtlein A, Mayr I, Appy M, Kühnler B, Buchthal J, Dippon C, Arnold G, Wächter T. botulinumtoxin improves both generic and disease-specific quality of life in cervical dystonia. Front Neurol. 2017;8:561. doi: 10.3389/fneur.2017.00561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Wenzel T, Schnider P, Wimmer A, Steinhoff N, Moraru E, Auff E. Psychiatric comorbidity in patients with spasmodic torticollis. J Psychosom Res. 1998;44:687–690. doi: 10.1016/S0022-3999(97)00229-8. [DOI] [PubMed] [Google Scholar]
  52. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20:649–655. doi: 10.1093/geront/20.6.649. [DOI] [PubMed] [Google Scholar]
  53. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist. 1986;26:260–266. doi: 10.1093/geront/26.3.260. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material 1 (DOCX 13 kb) (13.8KB, docx)

Articles from Journal of Neural Transmission are provided here courtesy of Springer

RESOURCES